Curated Wealth Partners LLC Purchases New Holdings in DaVita Inc. $DVA

Curated Wealth Partners LLC purchased a new stake in shares of DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,883 shares of the company’s stock, valued at approximately $3,478,000.

Several other large investors also recently added to or reduced their stakes in the company. Berkshire Hathaway Inc bought a new stake in DaVita during the 2nd quarter valued at $6,425,269,000. BlackRock Inc. bought a new position in DaVita during the second quarter valued at approximately $547,520,000. Dimensional Fund Advisors LP lifted its position in DaVita by 5.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock valued at $176,037,000 after purchasing an additional 56,336 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of DaVita in the second quarter valued at about $145,057,000. Finally, Bank of New York Mellon Corp bought a new position in DaVita during the 2nd quarter valued at approximately $101,127,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price target on shares of DaVita in a research note on Wednesday, August 5th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial dropped their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Raymond James Financial set a $220.00 price target on DaVita in a research note on Friday, August 7th. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Stock Performance

DaVita stock traded up $5.93 during midday trading on Thursday, hitting $186.63. 157,905 shares of the company’s stock were exchanged, compared to its average volume of 888,992. The company has a market cap of $11.91 billion, a PE ratio of 15.26, a P/E/G ratio of 0.47 and a beta of 0.80. The firm has a 50-day moving average of $180.23 and a two-hundred day moving average of $190.34. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. During the same quarter last year, the company earned $2.95 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts expect that DaVita Inc. will post 14.57 earnings per share for the current year.

About DaVita

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.